Biological and molecular characterization of HCB-289: a Brazilian head and neck cancer stem-like cell line

Abstract

In the present study, we describe the establishment of a Brazilian primary laryngeal HNSCC cell line, HCB-289, and isolated a putative cancer stem-like cell subpopulation. Primary cell culture was established from a mechanically disrupted fresh tumor by adherence to cell culture flask. Tumor cells were enriched by fibroblast elimination via differential trypsinization. After establishment, a CD44HIGH /ALDHHIGH subpopulation was isolated and purified from the parental HCB-289 cells by cell sorting. The CD44HIGH /ALDHHIGH proliferation rates and lower sensitivity to cisplatin, paclitaxel, cetuximab, and allitinib than its CD44LOW /ALDHLOW counterpart. Moreover, nanoString subpopulation exhibited greater clonogenic potential, lower miRNome analysis of these two subpopulations showed a higher expression of has-miR-205-5p CD44HIGH /ALDHHIGH and a lower expression of has-miR146a-5p (ratio = 0.08) in the subpopulation (ratio = 35.37). This novel study model will help in the understanding of the biology and molecular features of larynx squamous cell carcinoma, and its chemotherapeutic resistance. Implications:Our study established and characterized a new cell lineage from the Brazilian population derived from a solid primary tumor of the laryngeal HNSCC primary cell line and can be a useful tool for studying laryngeal squamous cell carcinoma

Unveiling the role of MGMT and DAPK hypermethylation in response to anti‐EGFR agents: Molecular insights for advancing HNSCC treatment

“…Cetuximab is a chimeric monoclonal antibody that precisely binds to EGFR on the cell surface, inhibiting downstream signal transduction, 66 potentially inducing immunological antitumor effects known as antibody‐dependent cell‐mediated cytotoxicity (ADCC) 67 . Despite the positive outcomes demonstrated by Cetuximab monotherapy, including an increased overall survival, only about 13% of recurrent or metastatic HNSCC cases respond to this treatment, which may help elucidate our results 47,68 …”

“…67 Despite the positive outcomes demonstrated by Cetuximab monotherapy, including an increased overall survival, only about 13% of recurrent or metastatic HNSCC cases respond to this treatment, which may help elucidate our results. 47,68…”